Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional IL-2 and/or BCG for Cutaneous Metastatic Melanoma
NCT03928275Phase 3Withdrawn
- Start
- Dec 2021
- Primary completion
- Sep 2022
- Modality
- Cytokines & Interferons, Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of bcg vaccine, aldesleukin in cutaneous metastatic melanoma. Planned start Dec 2021; status: withdrawn.
02
Drugs
bcg vaccinealdesleukin
03
Conditions
cutaneous metastatic melanoma
Beyond the preview
Go deeper on NCT03928275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928275.